Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Azithromycin may predispose cystic fibrosis patients to mycobacterial infection

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin.

2 Aug 2011

Insmed receives FDA clinical hold order for ARIKACE phase 3 trials in CF and NTM

Insmed Incorporated, a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on Insmed's phase 3 clinical trials for ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease.

2 Aug 2011

Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections

Cubist Pharmaceuticals, Inc. today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections.

1 Aug 2011

PathoGenetiX receives $4.0 million in first close of Series B financing

PathoGenetiX Inc., today announced that the Company has received $4.0 million in the first closing of its Series B financing.

1 Aug 2011

Tips to make family vacations less hazardous for kids and parents

Family vacations live in infamy. Sometimes it's for the lasting memories of family bonding and new wonders experienced together, and sometimes for the horrors of just trying to get to a destination.

29 Jul 2011

SMRT DNA sequencing technology reveals genetic profile of German E. coli bacteria

An international team of scientists has successfully employed single molecule, real-time DNA sequencing technology from Pacific Biosciences of California, Inc. to provide valuable insights into the pathogenicity and evolutionary origins of the highly virulent bacterium responsible for the German E. coli outbreak.

28 Jul 2011

UM researchers unravel genomic code of German E. coli bacteria

A team led by University of Maryland School of Medicine Institute for Genome Sciences researchers has unraveled the genomic code of the E. coli bacteria that caused the ongoing deadly outbreak in Germany that began in May 2011.

28 Jul 2011

Physician-targeted education campaign reduces outpatient antibiotic use in Quebec

Antibiotic overuse and resistance have emerged as major threats during the past two decades. Following an outbreak of Clostridium difficile infections, which often result from antibiotic use, health care professionals in Quebec, Canada targeted physicians and pharmacists with an education campaign that reduced outpatient antibiotic use, according to a study published in Clinical Infectious Diseases and now available online.

26 Jul 2011

Breathing problems trouble U.S. soldiers returning from Iraq and Afghanistan, speculation about inhaled toxins

According to a new study some U.S. soldiers returning from Iraq and Afghanistan are suffering unexplained breathing problems that may be related to exposure to unknown toxins.

21 Jul 2011

Pharmaceutical waste forms a whole new range of contaminants

The health implications of polluting the environment weigh increasingly on our public consciousness, and pharmaceutical wastes continue to be a main culprit. Now a Tel Aviv University researcher says that current testing for these dangerous contaminants isn't going far enough.

21 Jul 2011

Experts to explore wound healing abilities of dolphins

A Georgetown University Medical Center (GUMC) scientist who has previously discovered antimicrobial compounds in the skin of frogs and in the dogfish shark has now turned his attention to the remarkable wound healing abilities of dolphins.

21 Jul 2011

New rapid test accurately distinguishes bacterial and viral infections

Researchers at Ben-Gurion University of the Negev (BGU) have developed a new test that quickly and accurately distinguishes between bacterial and viral infections in as little as five hours.

21 Jul 2011

MDI, Eldan partner to distribute Detect-Ready MRSA Panel in Israel

Molecular Detection Inc. (MDI), a company developing Detect-Ready tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Eldan, a part on the Neopharm Group, today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA Panel in Israel and the Palestinian territories.

20 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Sigma introduces CompoZr Targeted Integration Kit – mRosa26

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich Corporation today announced the launch of CompoZr Targeted Integration Kit – mRosa26, which can precisely and rapidly integrate transgenes into the mouse genome at the Rosa26 safe harbor locus.

19 Jul 2011

EPA to expand Cooperative Research And Development Agreement with NanoLogix

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.

19 Jul 2011

JDR publishes study titled 'Public Health Surveillance of Dental Pain via Twitter'

The microblogging service Twitter is a new means for the public to communicate health concerns and could afford health care professionals new ways to communicate with patients.

19 Jul 2011

Thermo Fisher Scientific announces acquisition of TREK Diagnostic Systems

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has acquired TREK Diagnostic Systems, a global provider of microbiology solutions, including blood culture, microorganism identification and antibiotic susceptibility testing (AST) products, from Magellan Biosciences. Based near Cleveland, Ohio, the company had full year revenue in 2010 of $34 million and has 150 employees.

From Thermo Fisher Scientific Inc. 18 Jul 2011

Tea or coffee can protect from MRSA superbug

According to the latest study in the Annals of Family Medicine, people who drink tea or coffee regularly may be less likely to carry the Methicillin-resistant Staphylococcus aureus (MRSA) infection in their nostrils.

14 Jul 2011